AstraZeneca plc (AZN) Receives “Buy” Rating from Deutsche Bank AG
Deutsche Bank AG reaffirmed their buy rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Wednesday morning. Deutsche Bank AG currently has a GBX 5,800 ($75.71) target price on the biopharmaceutical company’s stock.
A number of other brokerages have also recently commented on AZN. Shore Capital reissued a hold rating on shares of AstraZeneca plc in a research report on Thursday, June 23rd. Credit Suisse Group AG reaffirmed an underperform rating and issued a GBX 4,000 ($52.21) price objective on shares of AstraZeneca plc in a research report on Wednesday, July 13th. Citigroup Inc. reaffirmed a buy rating on shares of AstraZeneca plc in a research report on Friday, September 23rd. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price objective on AstraZeneca plc and gave the company a sell rating in a research report on Wednesday, June 29th. Finally, JPMorgan Chase & Co. reaffirmed a neutral rating and issued a GBX 4,900 ($63.96) price objective on shares of AstraZeneca plc in a research report on Tuesday, August 23rd. Five analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) traded down 0.30% during trading on Wednesday, hitting GBX 5027.00. The stock had a trading volume of 851,968 shares. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The company has a 50-day moving average price of GBX 5,006.61 and a 200-day moving average price of GBX 4,427.08. The company’s market cap is GBX 63.59 billion.
The company also recently announced a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were issued a GBX 68.70 ($0.90) dividend. The ex-dividend date of this dividend was Thursday, August 11th. This represents a yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.